Peptide Therapy MD asks whether people survived
The thymosin alpha-1 sepsis trial asked who was alive at 28 days. I trust a survival comparison to settle this clinical claim; the immune biology explains why it was worth testing.
Thymosin alpha-1 in intensive care
The TESTS trial enrolled 1,106 adults with sepsis at 22 centres. At 28 days, all-cause mortality was 23.4% with thymosin alpha-1 and 24.1% with placebo. The difference was not statistically significant. A plausible treatment had reached a demanding human test and failed to establish the benefit that mattered most in that setting.
The immune-cell story initially sounded like the interesting part to me. Thymosin alpha-1 can influence the cells that recognise infection and organise a response; in sepsis, where an infection sets off a dangerous reaction that can damage organs, that sounds like a promising place to intervene. Then comes the survival result.
That disappointment gives this site its starting point. “Peptide therapy” is a reassuring phrase. For me, therapy earns its weight through what happens to people: survival in a sepsis trial, a specific fat reduction in HIV care, reliable recovery after an injury. Each claim asks for its own result.
The earlier sepsis result
There had been a reason for hope. In the earlier ETASS trial of 361 patients with severe sepsis, mortality at 28 days was 26.0% in the thymosin alpha-1 group and 35.0% in controls. The statistical picture was uncertain: nonstratified P=0.062 and log-rank P=0.049. Immune-cell measurements also improved.
The later trial tested the survival question in a larger, double-blinded comparison. Its disappointing answer deserves to alter expectations about sepsis. It leaves the peptide's other proposed uses to their own studies; a sepsis result cannot settle hepatitis or cancer care.
The long clinical history of thymosin alpha-1 makes this particularly interesting. Medical use abroad and a coherent biological explanation can coexist with a failed test of a particular treatment claim. That failed survival test warrants a change of mind, in my judgement.
Fat reduction, weight loss and healing
The other essays follow different clinical records. Tesamorelin has an approved use for excess abdominal fat in adults with HIV-associated lipodystrophy, an abnormal redistribution of fat. Its trials make a concrete case for that use. The retatrutide obesity trial recorded substantial weight loss, with safety questions still open and medicine approval absent. The BPC-157 literature remains dominated by preclinical work, despite a reputation for helping human injuries.
A single league table would flatten distinctions I care about. A change in body weight and a change in deaths answer different questions. Both can matter; the trouble begins when a demonstrated change acquires benefits that the study never measured.
- Thymosin alpha-1: the earlier sepsis signal, the larger test and the immune claims that survive around them.
- Tesamorelin: the approved fat indication, the scan findings and the limits of that approval.
- Retatrutide: weight loss, blood sugar, liver fat and the unanswered questions about longer-term health.
- BPC-157: the unusually small human record behind a broad recovery reputation.
The clinical comparison puts those outcomes beside one another. The reading list contains the studies and reviews behind them.